Document is current
Any future updates will be listed below
-
Authors
D’Agostino, Mattia
Rota-Scalabrini, Delia
Belotti, Angelo http://orcid.org/0000-0002-0617-3127
Bertamini, Luca
Arigoni, Maddalena
De Sabbata, Giovanni
Pietrantuono, Giuseppe
Pascarella, Anna http://orcid.org/0000-0002-0984-5080
Tosi, Patrizia
Pisani, Francesco
Pescosta, Norbert
Ruggeri, Marina
Rogers, Jennifer
Olivero, Martina
Garzia, Mariagrazia
Galieni, Piero
Annibali, Ombretta
Monaco, Federico http://orcid.org/0000-0002-4630-753X
Liberati, Anna Marina http://orcid.org/0000-0002-3686-3188
Palmieri, Salvatore
Stefanoni, Paola
Zamagni, Elena
Bruno, Benedetto
Calogero, Raffaele Adolfo
Boccadoro, Mario http://orcid.org/0000-0001-8130-5209
Musto, Pellegrino http://orcid.org/0000-0003-3277-6594
Gay, Francesca http://orcid.org/0000-0002-8619-412X
-
Funding
Funding for this research was provided by:
International Myeloma Society
- License Information
-
More Information
Article History
Received: 12 January 2024
Revised: 17 May 2024
Accepted: 23 May 2024
First Online: 7 June 2024
Competing interests
: MD has received honoraria for lectures for GlaxoSmithKline, Sanofi, and Janssen; has served on the advisory boards for GlaxoSmithKline, Sanofi, and Bristol Myers Squibb. AB has served on the advisory boards for Amgen, GlaxoSmithKline, Janssen, Pfizer. PG has served on the advisory boards for Takeda and Incyte. EZ recieved honoraria from Janssen, Bristol-Myers Squibb, Amgen, Takeda. BB has received honoraria from Amgen, Janssen, Novartis, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Jazz pharmaceuticals, Astrazeneca and Incyte; has served on the advisory boards for Amgen and Jazz pharmaceuticals. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GlaxoSmithKline; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and Mundipharma. PM has received honoraria from Celgene, Janssen, Takeda, Bristol Myers Squibb, Amgen, Novartis, Gilead, Jazz, Sanofi, AbbVie, and GlaxoSmithKline; has served on the advisory boards for Celgene, Janssen, Takeda, Bristol Myers Squibb, Amgen, Jazz, Sanofi, AbbVie, and GlaxoSmithKline. FG has received honoraria from Amgen, Celgene, Janssen, Takeda, Bristol Myers Squibb, AbbVie, and GlaxoSmithKline; has served on the advisory boards for Amgen, Celgene, Janssen, Takeda, Bristol Myers Squibb, AbbVie, GlaxoSmithKline, Roche, Adaptive Biotechnologies, Oncopeptides, bluebird bio, and Pfizer. The other authors declare no competing interests.
